Merck & Co. MRK Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 305%+3.2pp | 301.8%+10.3pp | 291.4%+9.2pp | 282.2%+8.4pp | |
| Net margin | 110.8%— | —— | —— | 105.6%— | |
| EBITDA margin | 142.5%— | —— | —— | 130.1%— | |
| Free cash flow margin | 89.1%-5.2pp | 94.3%+17.6pp | 76.7%-21.1pp | 97.8%+37.6pp | |
| Returns | |||||
| Return on equity | 151.2%— | —— | —— | 157.7%— | |
| Return on assets | 59.8%— | —— | —— | 59.9%— | |
| Return on invested capital | 93.4%— | —— | —— | 96.8%— | |
| Efficiency | |||||
| Asset turnover | 2.2×-0.1× | 2.3×+0.1× | 2.2×-0.1× | 2.3×+0.3× | |
| Inventory turnover | 13.8×-3.8× | 17.6×-3.8× | 21.5×-5.6× | 27×0.0× | |
| Liquidity | |||||
| Current ratio | 6×+0.6× | 5.4×+0.1× | 5.4×-0.4× | 5.7×+0.8× | |
| Quick ratio | 5.3×+0.4× | 4.9×+0.1× | 4.8×-0.4× | 5.2×+0.7× | |
| Cash ratio | 1.8×+0.2× | 1.6×+0.3× | 1.3×-0.5× | 1.8×+0.4× | |
| Leverage | |||||
| Debt-to-equity | 3.3×-0.3× | 3.7×+0.1× | 3.6×+0.5× | 3.1×-1.0× | |
| Debt-to-assets | 1.3×-0.1× | 1.4×0.0× | 1.4×+0.1× | 1.2×-0.2× | |
| Net debt / EBITDA | 5.2×— | —— | —— | 4.9×— | |
| Valuation | |||||
| Market capitalization | $899.32B-24.3% | $1.19T+7.9% | $1.1T+17.4% | $937.42B+21.0% | |
| Enterprise value | $1.02T-21.8% | $1.3T+7.1% | $1.22T+18.2% | $1.03T+17.5% | |
| Price / earnings | 50.6×— | —— | —— | 62.2×— | |
| Price / sales | 14×-4.9× | 18.9×+0.3× | 18.7×+2.4× | 16.3×-0.9× | |
| Price / book | 17.8×-9.6× | 27.4×+0.4× | 27×+5.6× | 21.4×-2.1× | |
| EV / EBITDA | 44.5×— | —— | —— | 55.3×— | |
| EV / sales | 15.8×-4.9× | 20.8×+0.1× | 20.6×+2.7× | 17.9×-1.5× | |
| Free cash flow yield | 25.8%+5.2pp | 20.6%+4.1pp | 16.5%-7.7pp | 24.2%+10.0pp | |
| Earnings yield | 31.9%— | —— | —— | 26.2%— | |
| Dividend yield | 14.5%+4.0pp | 10.5%-0.1pp | 10.6%-1.2pp | 11.8%-1.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Merck & Co.'s ratios come from?
- Every ratio is computed from Merck & Co.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
